Ryan D. Walsh

Ryan D. Walsh

Auto-generated profile, based on publicly available information

Ryan D. Walsh

Medical College of Wisconsin (ERD, KC, RDW), Milwaukee, Wisconsin; Department of Ophthalmology and Visual Sciences (KC, RDW); and Department of Neurology (RDW)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2016 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MWMelissa A. Wilson
Melissa A. Wilson
KGKelly Guld
Kelly Guld
SGsteven galetta
steven galetta
RWRyan D. Walsh
Ryan D. Walsh
JKJulia Kharlip
Julia Kharlip
LFLeslie A. Fecher
Leslie A. Fecher
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs). Case presentation Here we describe a patient treated with ipilimumab who experienced known IrAEs, including hypophysitis, as well as a profound vision loss due to optic neuritis. There are rare reports of optic neuritis occurring as an adverse event associated with ipilimumab treatment. Furthermore, the patient experienced multiple complications from high dose steroids used to manage his IrAEs. Conclusions This case highlights the need for recognition of atypical immune mediated processes associated with newer checkpoint inhibitor therapies including ipilimumab.

1 December 2019 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
SSSteven Seto
Steven Seto
ATAlison A. Teo
Alison A. Teo
RWRyan D. Walsh
Ryan D. Walsh

14 August 2023 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
HAHari R. Anandarajah
Hari R. Anandarajah
RWRyan D. Walsh
Ryan D. Walsh


3 January 2024 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
NSNikita Saladi
Nikita Saladi
HAHari Anandarajah
Hari Anandarajah
RWRyan D. Walsh
Ryan D. Walsh

20 May 2026 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
EDEmily R. Bs Daly
Emily R. Bs Daly
KCKasey Cooper
Kasey Cooper
RWRyan D. Walsh
Ryan D. Walsh
Background: This study describes the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of serum angiotensin-converting enzyme (s-ACE), and serum lysozyme in the diagnosis of sarcoid optic neuropathy (SON). Methods: We retrospectively reviewed the electronic medical record (EMR) of adult patients evaluated by neuro-ophthalmologists at Froedtert Hospital and the Medical College of Wisconsin clinics with a diagnosis of optic neuropathy (ON) from January 1, 2012, through July 1, 2023, who had s-ACE and/or serum lysozyme levels assessed. Potential patients for inclusion were identified using institutional data search tools. We then manually reviewed the EMR of each patient to verify whether inclusion parameters were met, and to gather relevant demographic and clinical data including s-ACE and lysozyme levels, and ON etiology. For the diagnosis of “Probable” or “Definite” SON, we relied on previously published consensus criteria for the diagnosis of neurosarcoidosis from the Neurosarcoidosis Consortium Consensus Group. The sensitivity, specificity, PPV, and NPV of s-ACE and lysozyme in the diagnosis of SON were calculated. For patients determined to meet criteria for a diagnosis of SON, we extracted additional data from the EMR including tissue biopsy location/s and findings; whether sarcoidosis diagnosis was already established before presentation with ON; whether the patient was taking corticosteroids or ACE-inhibitor (ACE-I) therapy at the time of laboratory evaluation; cerebrospinal fluid ACE (CSF-ACE) level; results of chest imaging; and results of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET) scans. Results: A total of 706 patients with ON were included. Of these 706 patients, 395 (56%) were women and 311 (44%) were men, with a median age of 51 years (range: 18–90). All 706 had an s-ACE level available, while 110 also had a lysozyme level available. Fourteen of the 706 (2%) patients met criteria for a diagnosis of “Probable” (n = 13) or “Definite” (n = 1) SON. Of these, 7 (50%) were women and 7 (50%) were men, with a median age of 42 years (range: 19–60). Seven of the 14 (50%) patients had a previously established diagnosis of sarcoidosis before presenting with ON. We found a sensitivity for s-ACE in diagnosing SON of 21.4%, and a specificity of 97%. The PPV of s-ACE was 12.5%, and the NPV was 98.4%. For lysozyme, we found a sensitivity of 33.3%, a specificity of 98%, PPV of 60%, and NPV of 94.3%. Conclusions: In diagnosing SON, we have found s-ACE to have a sensitivity of 21.4%, and a specificity of 97%. The PPV of s-ACE was 12.5% and the NPV was 98.4%. We have determined lysozyme in this setting to have a sensitivity of 33.3% and a specificity of 98%. The PPV of lysozyme was 60% and the NPV was 94.3%. The fact that s-ACE and lysozyme have low sensitivity for the diagnosis of SON indicates that neither of these tests is suitable as a general screening tool in this setting.